The Safety and Efficacy of Adalimumab Biosimilars in Inflammatory Diseases

EP: 1.The Need for Biosimilars in Inflammatory Diseases and Regulatory Requirements for Approval

EP: 2.An Overview of Adalimumab Biosimilars

EP: 3.The Pharmacological Aspects of Adalimumab Biosimilars

Now Viewing

EP: 4.The Safety and Efficacy of Adalimumab Biosimilars in Inflammatory Diseases

EP: 5.Impact of the Launch of Adalimumab Biosimilars in Different Clinical and Pharmacy Settings

EP: 6.The Role of Pharmacy Benefit Managers and Payers in Accessing Adalimumab Biosimilars

EP: 7.Strategies to Increase Adalimumab Biosimilar Uptake in Clinical Practice

EP: 8.Selecting Between Adalimumab Biosimilars for Your Patients

EP: 9.Switching From Adalimumab to a Biosimilar

EP: 10.Clinical Experience With Initiating Adalimumab Biosimilars

This is a video synopsis/summary of a panel discussion involving Jamie T. Brogan, MSN, APRN, FNP-BC; Kostas Botsoglou, MD; Jordan Axelrad, MD, MPH; Sophia Humphreys, PharmD, MHA; and Peter Lio, MD.

The discussion shifts to the safety and efficacy of biosimilars across various inflammatory diseases. The VOLTAIRE-RA trial, featuring an approved interchangeable biosimilar, demonstrates safety, tolerability, and efficacy within predefined primary endpoints, extending to conditions like psoriatic arthritis, ankylosing spondylitis, and uveitis. Biosimilars have also gained approval for psoriasis and hidradenitis suppurativa, indicating their versatility across disease states.

The conversation highlights the reassuring performance of biosimilars across different populations and conditions, underscoring their equivalence to originator drugs. Data from randomized trials show comparable patient outcomes and safety between originator and biosimilar therapies, providing clinical reassurance.

Extrapolating findings from one disease area to another, like from rheumatoid arthritis to inflammatory bowel diseases or psoriasis, enhances clinical accuracy and accessibility. With nearly a decade of biosimilar experience, studies consistently demonstrate no loss of efficacy and robust safety profiles, as evidenced by FDA data encompassing various therapeutic areas, including oncology and immunology.

Overall, the accumulated evidence fosters confidence in biosimilar use in the United States, supporting their integration into clinical practice across a spectrum of inflammatory diseases.

Video synopsis is AI-generated and reviewed by HCPLive editorial staff.